Journal ArticleDOI
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.
Hiroshi Ikeda,Teru Hideshima,Robert J. Lutz,Sonia Vallet,Samantha Pozzi,Loredana Santo,Elisabetta Calabrese,Benjamin Dälken,Christoph Uherek,Silke Aigner,Frank Osterroth,Mariateresa Fultiniti,Yutaka Okawa,Giulia Perrone,Gullu Gorgun,Hiroshi Yasui,Diana Cristia,Noopur Raje,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +20 more
Reads0
Chats0
TLDR
Strong evidence of in vitro and in vivo selective cytotoxicity of these immunoconjugates is demonstrated and the preclinical framework supporting evaluation of nBT062-based immunconjugates in clinical trials to improve patient outcome in MM is provided.About:
This article is published in Blood.The article was published on 2008-11-16. It has received 9 citations till now. The article focuses on the topics: Cytotoxicity & Bone marrow.read more
Citations
More filters
Journal ArticleDOI
Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
TL;DR: To enable antibodies to function as cytotoxic anticancer agents, they are modified either via attachment to protein toxins or highly potent, low-molecular-weight drugs, which represent a second revolution in antibody-mediated cancer therapy.
Journal ArticleDOI
Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells.
TL;DR: The considerations for selecting a target antigen, the design of the conjugate, and the pre-clinical and clinical experiences with the current generation of antibody-drug conjugates are reviewed.
Journal ArticleDOI
Advances in targeted therapeutic agents
TL;DR: This review includes a review of the various classes of targeted therapeutic agents, the types of disease-associated molecules being targeted by these agents and the challenges currently being encountered for the successful development of these various platforms for the treatment of disease.
Journal ArticleDOI
Antibody-drug conjugates in tumor therapy.
TL;DR: In this paper, the authors present the relevant patents in this research area and give background information on this interesting new technology and presents the relevant, recent patents in the research area, which are discussed owing to their eminent contribution and relevance to the field.
Patent
Uses of immunoconjugates targeting CD138
Frank Osterroth,Christoph Uherek,Christoph Bruecher,Benjamin Daelken,André Engling,Thomas Haeder,Andrea Wartenberg-Demand,Gabriele Niemann,Chantal Zuber,Niklas Czeloth,Silke Aigner,Steffen Zeng +11 more
TL;DR: In this article, methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases are discussed, either as the sole active ingredient or as part of an anticancer combination.